blue, 19%
A new molecule is emerging: Retatrutide A triple agonist targeting: GLP-1 GIP Glucagon Early clinical data suggests: Up to ~30% weight loss This could represent the next major leap in obesity treatment
This hormonal adjustment may temporarily affect the menstrual cycle, especially in women who already have hormone imbalances or are approaching perimenopause
By activating the receptors for both GIP and GLP-1, it helps improve insulin sensitivity, slows down digestion, and reduces hunger, leading to a feeling of fullness after eating smaller portions
Immune System Support Sleep deprivation and the stress of a new routine can tax the immune system
Using sterile equipment, disinfecting vial stoppers with alcohol before each puncture, minimizing unnecessary vial access, and refrigerating the peptide promptly after use all help support good laboratory handling practices